On February 25, 2025, Judge Colm F. Connolly of the U.S. District Court for the District of Delaware reversed a prior jury verdict in favor of Natera and vacated its $96.3 million (approximately R698 million) patent infringement judgment against CareDx.

The court found that two of Natera's patents (U.S. Patent Nos. 11,111,544 and 10,655,180) were invalid because the descriptions failed to describe the claimed inventions in sufficient detail. This ruling invalidated a January 2024 jury verdict finding CareDx's AlloSure and AlloSeq tests infringed Natera's patents.

On February 14, 2025, the USPTO, in a non-final examination opinion, also rejected the claims that CareDx had been found to have infringed in the litigation.Natera and CareDx are both companies focused on genetic testing and diagnostic technologies.

CareDx developed AlloSure, a non-invasive DNA test for detecting the occurrence of rejection in organ transplant recipients, which was first commercially launched in 2017.

In response to the court's decision, Natera said it plans to fight the case through legal avenues such as appeals.